Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:11:53.359Z.
Calculation as of: 2026-10-06T15:11:53.359Z.
Quote observation: 2026-10-06T15:10:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
PE RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$418.76M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$411.74M
PE Ratio
N/A
TTM Avg
22.42
3Y Avg
51.74
5Y Avg
51.74
Market Cap
$441.83M
PE Ratio
40.54
TTM Avg
54.06
3Y Avg
54.06
5Y Avg
54.06
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $418.76M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $411.74M | N/A | 22.42 | 51.74 | 51.74 |
| Neurogene Inc. (NGNE)vs › | $408.96M | N/A | 21.17 | 21.07 | 21.07 |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $407.27M | N/A | 178.15 | 100.22 | 67.93 |
| Carlsmed, Inc. (CARL)vs › | $403.70M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $435.23M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $438.74M | N/A | 138.05 | 184.03 | 168.06 |
| Assembly Biosciences, Inc. (ASMB)vs › | $441.83M | 40.54 | 54.06 | 54.06 | 54.06 |
| NeuroPace, Inc. (NPCE)vs › | $441.17M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$7.74
Forward EPS (Est.)
$-7.08
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
